Stifel Raises PT to $115 on Soleno Therapeutics Inc. (SLNO)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Stifel Reiterates Buy Rating on Soleno Therapeutics Inc. (SLNO)
July 10, 2025 7:24 AM EDTStifel analyst James Condulis reiterated a Buy rating and $115.00 price target on Soleno Therapeutics Inc. (NASDAQ: SLNO).
The analyst comments "SLNO reported preliminary 2Q results, including Vykat revenue expectations in the ~$31-$33MM range, and ~646 start-forms from 295 unique prescribers. In short, we think these numbers look... More
